Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Study sponsor: Jazz Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-28Actual
Enrollment · participants3Actual
Source updated2025-10-31Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.